Alnylam Pharmaceuticals, Inc. (ALNY) KPIs and segments
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Alnylam Pharmaceuticals · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Alnylam Pharmaceuticals: 50 chỉ số vận hành, trong đó có Total TTR Franchise YoY Revenue Growth at Constant, AMVUTTRA YoY Revenue Growth at Constant Exchange Rate và ONPATTRO YoY Revenue Growth at Constant Exchange Rate, lấy từ 254 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net product revenues($M) | 1,292 | 1,172 | 1,036 | 995 | 851 | 672 | 469 | 451 | 420 | 410 | 365 | 346 | |
AMVUTTRA($M)3 | 1,130 | 1,012 | 890 | 827 | 685 | 492 | 310 | 287 | 259 | 230 | 195 | 175 | |
United States($M) | 909 | 809 | 703 | 642 | 530 | 361 | 198 | 183 | 169 | 148 | 130 | 122 | |
Europe($M) | 131 | 119 | 113 | 121 | 112 | 92.9 | 80.1 | 69.8 | 65.1 | 56.8 | 43.7 | 30.3 | |
Rest of World (primarily Japan)($M) | 91.0 | 83.7 | 74.1 | 64.0 | 43.0 | 37.7 | 31.9 | 33.4 | 24.8 | 24.9 | 21.3 | 22.8 | |
Royalty revenue($M) | 94.7 | 71.7 | 49.0 | 61.4 | 46.2 | 40.0 | 26.5 | 35.4 | 23.4 | 22.4 | 10.6 | 17.0 | |
GIVLAARI($M)3 | 89.5 | 89.8 | 74.4 | 86.8 | 73.9 | 80.8 | 67.0 | 64.6 | 71.0 | 62.1 | 58.1 | 59.3 | |
United States($M) | 57.5 | 58 | 49.1 | 56.3 | 50.4 | 55.2 | 43.8 | 45.0 | 40.4 | 41.2 | 38.7 | 39.5 | |
Europe($M) | 20.9 | 24.3 | 20.3 | 19.5 | 18.7 | 21.0 | 18.5 | 18.0 | 16.3 | 16.3 | 15.3 | 16.5 | |
Rest of World (primarily Japan)($M) | 11.2 | 7.44 | 5.01 | 11.0 | 4.74 | 4.73 | 4.63 | 1.60 | 14.4 | 4.59 | 4.01 | 3.29 | |
Collaborations($M) | 71.5 | 47.2 | 82.1 | 40.9 | 352 | 61.5 | 99.2 | 107 | 57.4 | 227 | 119 | 76.4 | |
OXLUMO($M)3 | 52.5 | 52.1 | 51.3 | 49.6 | 52.8 | 46.9 | 42.1 | 43.6 | 40.2 | 40.6 | 42.6 | 32.7 | |
Europe($M) | 23.2 | 22.7 | 24.4 | 22.8 | 22.3 | 21.9 | 21.0 | 18.8 | 20.0 | 20.5 | 21.4 | 19.4 | |
United States($M) | 18.4 | 18.5 | 17.0 | 17.6 | 20.7 | 16.0 | 14.1 | 18.8 | 14.9 | 15.7 | 13.3 | 10.6 | |
Rest of World (primarily Japan)($M) | 10.9 | 10.9 | 9.97 | 9.24 | 9.76 | 8.92 | 7.00 | 5.97 | 5.31 | 4.36 | 7.89 | 2.72 | |
ONPATTRO($M)3 | 19.6 | 18.5 | 20.5 | 31.7 | 39.1 | 52.5 | 49.5 | 56.1 | 50.3 | 77.2 | 69.2 | 79.0 | |
United States($M) | 9.71 | 9.86 | 10.2 | 12.0 | 12.5 | 22.1 | 15.6 | 19.9 | 16.2 | 22.1 | 16.5 | 20.5 | |
Rest of World (primarily Japan)($M) | 5.13 | 3.09 | 2.75 | 7.70 | 6.92 | 9.24 | 7.38 | 8.07 | 9.76 | 18.1 | 7.99 | 14.0 | |
Europe($M) | 4.76 | 5.51 | 7.57 | 12.0 | 19.7 | 21.2 | 26.5 | 28.1 | 24.3 | 37.1 | 44.7 | 44.5 | |
Total TTR Franchise YoY Revenue Growth at Constant Exchange Rate (CER)(%)1 | 60.0% | 89.0% | 150.0% | 149.0% | 131.0% | 75.0% | 38.0% | 34.0% | 35.0% | 39.0% | 30.0% | 31.0% | |
Total TTR Franchise YoY Revenue Growth (As Reported)(%) | 59.0% | 89.0% | 153.0% | 151.0% | 135.0% | 77.0% | 36.0% | 35.0% | 34.0% | 37.0% | 29.0% | 33.0% | |
AMVUTTRA (vutrisiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4 | 66.0% | 106.0% | 183.0% | 187.0% | 162.0% | 112.0% | 75.0% | 77.0% | 101,768.0% | ||||
AMVUTTRA Worldwide YoY Revenue Growth (As Reported)(%) | 65.0% | 106.0% | 187.0% | 189.0% | 165.0% | 114.0% | 59.0% | 74.0% | 74.0% | 195,241.0% | |||
AMVUTTRA — United States YoY Revenue Growth (As Reported)(%) | 71.0% | 124.0% | 255.0% | 214.0% | 143.0% | 52.0% | 49.0% | 54.0% | 65.0% | ||||
AMVUTTRA — Europe YoY Revenue Growth (As Reported)(%) | 17.0% | 28.0% | 41.0% | 72.0% | 64.0% | 83.0% | 235.0% | 294.0% | |||||
AMVUTTRA — Rest of World YoY Revenue Growth (As Reported)(%) | 112.0% | 122.0% | 132.0% | 73.0% | 52.0% | 50.0% | 57.0% | 17.0% | 33.0% | ||||
ONPATTRO (patisiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4 | -50.0% | -65.0% | -61.0% | -45.0% | -25.0% | -33.0% | -38.0% | -15.0% | 102,493.0% | ||||
ONPATTRO Worldwide YoY Revenue Growth (As Reported)(%) | -50.0% | -65.0% | -59.0% | -44.0% | -22.0% | -32.0% | -29.0% | -38.0% | -16.0% | 69,217.0% | |||
ONPATTRO — United States YoY Revenue Growth (As Reported)(%) | -22.0% | -55.0% | -35.0% | -23.0% | 0.0% | -6.0% | -26.0% | -13.0% | -45.0% | ||||
ONPATTRO — Europe YoY Revenue Growth (As Reported)(%) | -76.0% | -74.0% | -71.0% | -19.0% | -43.0% | -41.0% | -52.0% | -34.0% | -25.0% | ||||
ONPATTRO — Rest of World YoY Revenue Growth (As Reported)(%) | -26.0% | -67.0% | -63.0% | -29.0% | -49.0% | -8.0% | 4.0% | 90.0% | -39.0% | ||||
Total TTR Franchise Net Product Revenues (AMVUTTRA + ONPATTRO)($M) | 1,150 | 1,030 | 910 | 858 | 724 | 545 | 360 | 343 | 309 | 307 | 265 | ||
Total Rare Franchise YoY Revenue Growth at Constant Exchange Rate (CER)(%)1 | 13.0% | 10.0% | 10.0% | 23.0% | 11.0% | 23.0% | 11.0% | 17.0% | 82,884.0% | 82,111.0% | 72,067.0% | ||
Total Rare Franchise YoY Revenue Growth (As Reported)(%) | 12.0% | 11.0% | 15.0% | 26.0% | 14.0% | 24.0% | 8.0% | 18.0% | 111,263.0% | 102,735.0% | 100,705.0% | ||
GIVLAARI (givosiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4 | 22.0% | 10.0% | 7.0% | 32.0% | 2.0% | 29.0% | 31.0% | 8.0% | 21.0% | 24.0% | |||
GIVLAARI Worldwide YoY Revenue Growth (As Reported)(%) | 21.0% | 11.0% | 11.0% | 34.0% | 4.0% | 30.0% | 15.0% | 31.0% | 7.0% | 21.0% | 26.0% | ||
GIVLAARI — United States YoY Revenue Growth (As Reported)(%) | 14.0% | 5.0% | 12.0% | 25.0% | 34.0% | 13.0% | 9.0% | 17.0% | 28.0% | ||||
GIVLAARI — Europe YoY Revenue Growth (As Reported)(%) | 12.0% | 16.0% | 9.0% | 15.0% | 29.0% | 21.0% | 31.0% | 16.0% | 6.0% | ||||
GIVLAARI — Rest of World YoY Revenue Growth (As Reported)(%) | 135.0% | 57.0% | 8.0% | -67.0% | 3.0% | 15.0% | 206.0% | -47.0% | 28.0% | ||||
OXLUMO (lumasiran) YoY Revenue Growth at Constant Exchange Rate (CER)(%)4 | 0.0% | 9.0% | 13.0% | 10.0% | 27.0% | 13.0% | 40.0% | 68.0% | 75.0% | 32.0% | |||
OXLUMO Worldwide YoY Revenue Growth (As Reported)(%) | -1.0% | 11.0% | 22.0% | 14.0% | 31.0% | 15.0% | -1.0% | 40.0% | 68.0% | 77.0% | 37.0% | ||
OXLUMO — United States YoY Revenue Growth (As Reported)(%) | -11.0% | 16.0% | 20.0% | 39.0% | 2.0% | 6.0% | 54.0% | 79.0% | 47.0% | ||||
OXLUMO — Europe YoY Revenue Growth (As Reported)(%) | 4.0% | 3.0% | 16.0% | 12.0% | 7.0% | -2.0% | 32.0% | 68.0% | 61.0% | ||||
OXLUMO — Rest of World YoY Revenue Growth (As Reported)(%) | 11.0% | 22.0% | 42.0% | 84.0% | 105.0% | -11.0% | 35.0% | 36.0% | 340.0% | ||||
Total Rare Franchise Net Product Revenues (GIVLAARI + OXLUMO)($M) | 142 | 142 | 126 | 136 | 127 | 128 | 109 | 108 | 111 | 103 | 101 | ||
Combined Net Product Revenues YoY Growth at Constant Exchange Rate (CER)(%)4 | 53.0% | 74.0% | 117.0% | 119.0% | 99.0% | 62.0% | 30.0% | 29.0% | 35.0% | 35.0% | 32.0% | 30.0% | |
Combined Net Product Revenues YoY Growth (As Reported)(%) | 52.0% | 74.0% | 121.0% | 121.0% | 103.0% | 64.0% | 28.0% | 30.0% | 34.0% | 34.0% | 32.0% | 32.0% | |
Total Consolidated Revenues YoY Growth at Constant Exchange Rate (CER)(%) | 17.0% | 67.0% | 93.0% | 83.0% | 147.0% | 16.0% | 22.0% | 34.0% | 55.0% | 29.0% | |||
Total Consolidated Revenues YoY Growth (As Reported)(%) | 17.0% | 67.0% | 96.0% | 85.0% | 149.0% | 17.0% | 20.0% | 35.0% | -33.0% | 107.0% | 55.0% | 31.0% | |
Cost of Goods Sold as % of Net Product Revenues(%) | 28.0% | 25.4% | 20.0% | 26.9% | 23.2% | 21.1% | 15.0% | 22.8% | 19.5% | 16.4% | 15.0% | 20.8% | |
Full-Year Guidance — Combined Net Product Revenue Growth at CER (Upper Bound)(%)3 | 70.0% | 70.0% | 77.0% | 77.0% | 84.0% | 68.0% | 39.0% | 21.0% | |||||
Full-Year Guidance — Combined Net Product Revenue Growth at CER (Lower Bound)(%) | 57.0% | 57.0% | 64.0% | 64.0% | 78.0% | 59.0% | 26.0% | 13.0% | |||||
Full-Year Guidance — Combined Net Product Revenue Growth As Reported (Upper Bound)(%) | 71.0% | 71.0% | 77.0% | 77.0% | 85.0% | 70.0% | 37.0% | 33.0% | 33.0% | 21.0% | 21.0% | ||
Full-Year Guidance — Combined Net Product Revenue Growth As Reported (Lower Bound)(%) | 57.0% | 57.0% | 64.0% | 64.0% | 79.0% | 61.0% | 25.0% | 27.0% | 27.0% | 13.0% | 13.0% | ||
Full-Year Guidance — Combined Net Product Revenues (Upper Bound)($M)9 | 5,100 | 5,100 | 5,300 | 5,300 | 3,050 | 2,800 | 2,250 | 1,650 | 1,650 | 1,500 | 1,500 | ||
Full-Year Guidance — Combined Net Product Revenues (Lower Bound)($M) | 4,700 | 4,700 | 4,900 | 4,900 | 2,950 | 2,650 | 2,050 | 1,575 | 1,575 | 1,400 | 1,400 | ||
Full-Year Guidance — Total TTR Net Product Revenues (Upper Bound)($M) | 4,500 | 4,500 | 4,700 | 4,700 | 2,525 | 2,275 | 1,725 | ||||||
Full-Year Guidance — Total TTR Net Product Revenues (Lower Bound)($M) | 4,200 | 4,200 | 4,400 | 4,400 | 2,475 | 2,175 | 1,600 | ||||||
Full-Year Guidance — Total Rare Net Product Revenues (Upper Bound)($M) | 600 | 600 | 600 | 600 | 525 | 525 | 525 | ||||||
Full-Year Guidance — Total Rare Net Product Revenues (Lower Bound)($M) | 500 | 500 | 500 | 500 | 475 | 475 | 450 | ||||||
Full-Year Guidance — Net Revenues from Collaborations & Royalties (Upper Bound)($M) | 625 | 625 | 500 | 500 | 750 | 750 | 750 | 650 | 650 | 425 | 425 | ||
Full-Year Guidance — Net Revenues from Collaborations & Royalties (Lower Bound)($M) | 575 | 575 | 400 | 400 | 650 | 650 | 650 | 575 | 575 | 325 | 325 | ||
Full-Year Guidance — Non-GAAP Combined R&D and SG&A Expenses (Upper Bound)($M) | 2,800 | 2,800 | 2,800 | 2,800 | 2,200 | 2,200 | 2,200 | 1,875 | 1,875 | 1,775 | 1,775 | ||
Full-Year Guidance — Non-GAAP Combined R&D and SG&A Expenses (Lower Bound)($M) | 2,700 | 2,700 | 2,700 | 2,700 | 2,150 | 2,100 | 2,100 | 1,775 | 1,775 | 1,675 | 1,675 | ||
Combined Net Product Revenues (Worldwide)($M)2 | 1,292 | 1,172 | 1,036 | 995 | 851 | 672 | 469 | 451 | 420 | 410 | 365 | 346 | |
Total Consolidated Revenues (Product + Collaborations + Royalties)($M) | 1,458 | 1,291 | 1,167 | 1,097 | 1,249 | 774 | 594 | 593 | 501 | 660 | 494 | 440 | |
Cost of Goods Sold (GAAP)($M) | 362 | 298 | 208 | 268 | 197 | 142 | 70.2 | 103 | 82 | 67.3 | 54.6 | 72 | |
Royalty Revenue YoY Growth (As Reported)(%)1 | 105.0% | 79.0% | 85.0% | 73.0% | 98.0% | 78.0% | 149.0% | 136.0% | 211.0% | 63.0% | |||
Royalty Revenue YoY Growth at Constant Exchange Rate (CER)(%) | 105.0% | 79.0% | 85.0% | 73.0% | 98.0% | 78.0% | 149.0% | ||||||
Net Revenues from Collaborations YoY Growth (As Reported)(%)5 | -80.0% | -23.0% | -17.0% | -62.0% | -73.0% | -16.0% | -87.0% | 225.0% | |||||
Net Revenues from Collaborations YoY Growth at Constant Exchange Rate (CER)(%) | -80.0% | -23.0% | -17.0% | -62.0% | -73.0% | -16.0% | |||||||
Regeneron Collaboration Revenue YoY Growth (As Reported)(%) | 43.0% | -85.0% | -9.0% | -74.0% | -41.0% | -84.0% | 91.0% | -53.0% | 34.0% | ||||
Regeneron Collaboration Revenue YoY Growth at Constant Exchange Rate (CER)(%) | 43.0% | -85.0% | -9.0% | -74.0% | -41.0% | -84.0% | 91.0% | ||||||
Roche Collaboration Revenue YoY Growth (As Reported)(%) | -88.0% | 129.0% | 109.0% | 174.0% | 361,927.0% | 11.0% | -77.0% | -95.0% | 91,186.0% | ||||
Roche Collaboration Revenue YoY Growth at Constant Exchange Rate (CER)(%) | -88.0% | 129.0% | 109.0% | 174.0% | 11.0% | -77.0% | |||||||
Remaining Performance Obligations (RPO) — Regeneron Collaboration Transaction Price($M)1 | 20.9 | 28.2 | 27.4 | 34.1 | 34.3 | 46.8 | 169 | 167 | 170 | 676 | 335 | ||
Remaining Performance Obligations (RPO) — Roche (Zilebesiran) Collaboration Transaction Price($M) | 792 | 830 | 870 | 904 | 936 | 870 | 922 | 922 | 922 | 523 | |||
Net Revenues from Collaborations (Total)($M)3 | 71.5 | 47.2 | 82.1 | 41 | 352 | 61.5 | 99.2 | 107 | 57.4 | 227 | 119 | 76.4 | |
Roche Collaboration Revenue — Total (Zilebesiran Cardiovascular Alliance)($M)2 | 39.1 | 41.9 | 35.6 | 33 | 327 | 18.3 | 17.1 | 12 | 16.3 | 16.5 | 72.2 | 27.6 | |
Roche — Development Services Revenue($M) | 37.6 | 40.2 | 34.4 | 31.3 | 25.2 | 16.7 | 15.8 | 10.9 | 14.9 | 12.8 | 7.20 | 23.8 | |
Roche — Other Services & Milestone Revenue($M) | 1.60 | 1.70 | 1.20 | 1.60 | 1.40 | 1.60 | 1.20 | 1.10 | 1.40 | 3.70 | |||
Regeneron Collaboration Revenue — Total (CNS, Ocular & C5 Programs)($M)4 | 32.3 | 5 | 46.3 | 7.80 | 22.5 | 32.5 | 51 | 30.7 | 38 | 207 | 26.8 | 27.8 | |
Regeneron — Research & Development Services Revenue($M) | 7.30 | -0.80 | 6.60 | 0.20 | 12.5 | 13 | 13.8 | 9.30 | 11.1 | 4 | 14.7 | 13.5 | |
Regeneron — C5 Cemdisiran License Revenue($M) | 0 | 0 | 0 | 0.30 | 0 | 0 | 21.5 | 19.4 | 8.40 | 8.80 | 1.70 | -21.1 | |
Regeneron — Manufacturing & Technology Transfer Revenue($M) | 0 | 0 | 0 | 0 | 0 | 0 | 2.40 | 0 | 0 | 0 | |||
Regeneron — Other Program License Revenue($M) | 25 | 5.80 | 39.7 | 7.30 | 10 | 19.6 | 13.3 | 1.90 | 18.4 | 3.10 | |||
Other Collaborations Revenue (PeptiDream, Vir Biotechnology & Other)($M) | 0 | 0.30 | 0.10 | 0.20 | 2.60 | 10.7 | 31.1 | 4.30 | 0.20 | 1.10 | 2.60 | 2.10 | |
Contract Liabilities (Deferred Collaboration Revenue) — Current Balance($M)3 | 11.7 | 4 | 3.20 | 4.80 | 2.50 | 15.1 | 28.2 | 55.5 | 71 | 69 | 76.8 | 103 | |
Contract Liabilities — Collaborations Current($M) | 11.7 | 4 | 3.20 | 4.80 | 2.50 | 15.1 | 28.2 | 55.5 | 72 | 71.2 | 262 | 291 | |
Contract Liabilities — Regeneron Research Services (Current)($M) | 11.7 | 4 | 3.20 | 4.80 | 2.50 | 15.1 | 27.3 | 41.2 | 45.5 | 41.5 | 48.7 | 63.4 | |
Collaboration Revenue Recognized from Beginning Contract Liability Balance($M) | 4 | -0.80 | 4.80 | 0.20 | 12.5 | 13 | 28.1 | 17.9 | 19.5 | 200 | 20.4 | -1.50 | |
Blackstone Sale of Future Royalties (Leqvio) — Effective Interest Rate(%)4 | 15.0% | 14.0% | 11.0% | 10.0% | 10.0% | 10.0% | 9.0% | 9.0% | 9.0% | 8.0% | |||
Vutrisiran Development Funding Liability — Effective Interest Rate(%) | 47.0% | 51.0% | 49.0% | 46.0% | |||||||||
Zilebesiran Development Funding Liability — Effective Interest Rate(%) | 31.0% | 31.0% | 32.0% | 32.0% | |||||||||
1.00% Convertible Senior Notes due 2027 — Effective Interest Rate(%) | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% | |||||||
0.00% Convertible Senior Notes due 2028 — Effective Interest Rate(%) | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% | ||||||||
Gross-to-Net (GTN) Accrued Rebates, Chargebacks & Discounts — Ending Reserve Balance($M)6 | 557 | 503 | 477 | 426 | 559 | 474 | 362 | 346 | |||||
Accrued Government & Managed Care Rebates & Wholesaler Chargebacks — Ending Balance($M) | 524 | 473 | 449 | 400 | 537 | 450 | 351 | 326 | |||||
Accrued Co-Pay Assistance, Prompt-Pay Cash Discounts & Other Incentives — Ending Balance($M) | 32.6 | 29.6 | 27.7 | 25.8 | 10.9 | 20.3 | |||||||
GTN Rollforward — Provisions Recorded for Sales Made in Current Period (Total)($M)2 | 399 | 346 | 320 | 287 | 244 | ||||||||
Provisions for Current Period Sales — Chargebacks & Rebates($M) | 366 | 313 | 290 | 257 | 220 | ||||||||
Provisions for Current Period Sales — Other Incentives($M) | 33.3 | 32.6 | 30 | ||||||||||
GTN Rollforward — Provisions (Credits) for Sales Made in Prior Periods (Total)($M)2 | 3.90 | 1.10 | 2.10 | 5.30 | 6.30 | ||||||||
Prior Period Adjustments — Chargebacks & Rebates($M) | 3.90 | 1.10 | 1.10 | 5.30 | 6.30 | ||||||||
Prior Period Adjustments — Other Incentives($M) | 0 | 0 | 1 | ||||||||||
GTN Rollforward — Payments & Credits Issued Relating to Current Period Sales (Total)($M)2 | -290 | -219 | -161 | -258 | -144 | ||||||||
Payments/Credits for Current Period Sales — Chargebacks & Rebates($M) | -261 | -190 | -147 | -234 | -118 | ||||||||
Payments/Credits for Current Period Sales — Other Incentives($M) | -29.3 | -28.2 | -14.2 | ||||||||||
GTN Rollforward — Payments & Credits Issued Relating to Prior Period Sales (Total)($M)2 | -50.7 | -100 | -105 | -157 | -8.80 | ||||||||
Payments/Credits for Prior Period Sales — Chargebacks & Rebates($M) | -49.8 | -97.5 | -92.2 | -155 | -8.80 | ||||||||
Payments/Credits for Prior Period Sales — Other Incentives($M) | -0.90 | -2.50 | -12.9 | ||||||||||
Inventories by Manufacturing Stage — Total Inventories (Current + Noncurrent)($M)5 | 117 | 117 | 116 | 112 | 96.6 | 100 | 110 | 115 | 115 | 120 | 126 | 125 | |
Current Inventories, Net($M) | 106 | 97.1 | 84 | 82.7 | 75.4 | 71.7 | 65.6 | 78.5 | 76 | 84 | 94 | 89.2 | |
Raw Materials($M) | 18 | 13.9 | 11.7 | 14.2 | 22.2 | 22.9 | 23.4 | 24 | 22.4 | 26 | 25.4 | 23.4 | |
Work in Process (siRNA Drug Substance & Bulk Intermediates)($M) | 58.8 | 59 | 65.5 | 65.1 | 35.5 | 43.8 | 54 | 65 | 69.9 | 66.5 | 76.1 | 77 | |
Finished Goods (Labeled Commercial Vials & Syringes)($M) | 40.4 | 44 | 39 | 32.3 | 38.9 | 33.8 | 33 | 26.4 | 23.1 | 27.9 | 24.8 | 25.1 | |
Noncurrent Inventories (Long-Term Pre-Launch & Commercial Stock in Other Assets)($M) | 11.3 | 19.9 | 32.1 | 28.9 | 21.2 | 28.7 | 44.8 | 36.9 | 39.4 | 36.4 | 32.3 | 36.3 | |
Accounts Receivable Disaggregation — Total Accounts Receivable, Net($M)2 | 1,085 | 913 | 884 | 778 | 965 | 567 | 418 | 405 | 354 | 310 | 321 | 328 | |
Trade Accounts Receivable from Product Sales, Net($M) | 906 | 788 | 727 | 670 | 573 | 475 | 312 | 270 | 266 | 249 | 240 | 210 | |
Billed & Unbilled Collaboration Receivables($M) | 89.6 | 58.7 | 109 | 48.8 | 347 | 55.6 | 80.4 | 103 | 64.6 | 39.5 | 66.3 | 99.6 | |
Accrued Expenses — Total Current Balance($M) | 1,236 | 1,096 | 947 | 1,080 | 1,154 | 919 | 704 | 794 | 946 | 809 | 699 | 713 | |
GAAP Research & Development Expenses (Total)($M)5 | 409 | 413 | 365 | 372 | 359 | 324 | 265 | 300 | 271 | 294 | 261 | 272 | |
R&D by Function — Clinical Trial & Outside Manufacturing Services($M) | 240 | 244 | 199 | 202 | 171 | 141 | 127 | 129 | 135 | 120 | 126 | ||
R&D by Function — Compensation & Related Personnel Benefits($M) | 122 | 125 | 124 | 128 | 146 | 143 | 99.2 | 129 | 95.1 | 135 | 96.4 | ||
R&D by Function — Occupancy, Lab Supplies & All Other R&D($M) | 47.3 | 43.5 | 41.4 | 42.9 | 42 | 39.5 | 38.6 | 41.7 | 40.9 | 39.8 | 39.1 | ||
R&D Costs Incurred Under Regeneron Collaboration($M) | 9.80 | 12.2 | 11 | 15.9 | 14.6 | 12.5 | 18.9 | 10.9 | 27.9 | 14.3 | 18.7 | 50.4 | |
R&D Costs Incurred Under Roche (Zilebesiran) Collaboration($M) | 66.5 | 73.3 | 61.2 | 54.4 | 44.8 | 31 | 29.7 | 20.6 | 27.8 | 26.2 | 18.1 | 44.6 | |
GAAP Selling, General & Administrative Expenses (Total)($M)3 | 342 | 348 | 323 | 325 | 322 | 323 | 240 | 295 | 221 | 248 | 211 | 198 | |
SG&A by Function — Compensation & Related Personnel Benefits($M) | 168 | 167 | 163 | 157 | 189 | 191 | 131 | 160 | 116 | 138 | 117 | ||
SG&A by Function — Commercial, Consulting & Professional Services($M) | 119 | 121 | 105 | 113 | 88.7 | 82.6 | 64.7 | 82.7 | 68.3 | 66.7 | 56.8 | ||
SG&A by Function — Occupancy & All Other SG&A($M) | 55.5 | 60.6 | 54.2 | 55.5 | 44.7 | 49.4 | 43.8 | 52.3 | 37 | 44 | 36.7 | ||
Non-GAAP Operating Income (Loss)($M)5 | 424,916 | 318,066 | 338,790 | 203,350 | 476,193 | 95,481 | 74,789 | -13,514 | -31,101 | 137,902 | 1,912 | -74,410 | |
Non-GAAP Net Income (Loss)($M) | 2,241,910 | 251,801 | 273,038 | 169,753 | 396,180 | 44,122 | -1,287 | 8,048 | -64,199 | 73,766 | -20,666 | -96,643 | |
Non-GAAP Diluted Net Income (Loss) Per Common Share($) | 16.26 | 1.84 | 1.99 | 1.25 | 2.90 | 0.32 | -0.01 | 0.06 | -0.50 | 0.56 | -0.16 | -0.77 | |
Non-GAAP Basic Net Income (Loss) Per Common Share($) | 16.75 | 1.88 | 2.05 | 1.28 | 3.01 | 0.34 | -0.01 | 0.06 | -0.50 | 0.58 | -0.16 | -0.77 | |
Non-GAAP Research & Development Expenses (Ex-SBC & Milestone Payments)($M) | 375,677 | 377,240 | 334,754 | 340,898 | 310,089 | 274,069 | 241,324 | 259,544 | 251,132 | 246,027 | 241,780 | 253,056 | |
Non-GAAP Selling, General & Administrative Expenses (Ex-SBC)($M) | 295,743 | 297,191 | 282,509 | 285,062 | 262,590 | 261,186 | 207,035 | 244,319 | 194,983 | 207,224 | 184,665 | 175,214 | |
Blackstone Leqvio Sale of Future Royalties — Noncurrent Liability Carrying Value($M)19 | 1,539 | 1,517 | 1,490 | 1,479 | 1,465 | 1,443 | 1,421 | 1,447 | 1,424 | 1,405 | 1,383 | 1,377 | |
Blackstone Leqvio Sale of Future Royalties — Current Portion($M) | 189 | 167 | 122 | 119 | 112 | ||||||||
Blackstone Leqvio Liability — Estimated Fair Value (Level 3)($M) | 2,030 | 1,960 | 1,670 | 1,610 | |||||||||
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties($M) | 57.9 | 53.2 | 40.5 | 37.5 | 40.9 | 36.5 | 35 | 35.3 | 30.7 | 29.5 | 31.6 | 27.6 | |
Royalty Payments Remitted to Blackstone on Leqvio Sales($M) | 35.3 | 26.1 | 30.1 | 23.2 | 18.7 | 14.4 | 61.7 | 12.3 | 10.9 | 8.10 | 25.7 | 5.40 | |
Total Noncurrent Liabilities Related to Sale of Future Royalties & Development Funding($M) | 1,463 | 1,462 | 1,470 | 1,470 | 1,334 | ||||||||
Total Current Liabilities Related to Sale of Future Royalties & Development Funding($M) | 272 | 259 | 228 | 220 | 113 | ||||||||
Vutrisiran Development Funding Liability (Blackstone) — Level 3 Balance($M) | 170 | 181 | 188 | 194 | 190 | ||||||||
Vutrisiran Development Funding Liability — Noncurrent Portion($M) | 94.4 | 91.2 | 89.4 | 99.7 | |||||||||
Vutrisiran Development Funding Liability — Current Portion($M) | 76 | 89.9 | 98.5 | 94.5 | |||||||||
Vutrisiran Development Funding Liability — Fair Value($M) | 479 | 555 | 558 | 541 | |||||||||
Vutrisiran Development Funding Liability — Interest Expense($M) | 21.3 | 23.9 | 23.9 | ||||||||||
Vutrisiran Development Funding Liability — Payments Made($M) | -32 | -30.8 | -30.1 | ||||||||||
Zilebesiran Development Funding Liability — Level 3 Balance($M) | 25.2 | 22.3 | 19.6 | 17.1 | 25.3 | ||||||||
Zilebesiran Development Funding Liability — Noncurrent Portion($M) | 18.3 | 20.2 | 12.1 | 10.3 | |||||||||
Zilebesiran Development Funding Liability — Current Portion($M) | 6.90 | 2.10 | 7.50 | 6.80 | |||||||||
Zilebesiran Development Funding Liability — Fair Value($M) | 120 | 120 | 118 | 116 | |||||||||
Zilebesiran Development Funding Liability — New Funding Additions($M) | 6 | 6 | 6 | ||||||||||
Zilebesiran Development Funding Liability — Interest Expense($M) | 2.20 | 2 | 1.90 | ||||||||||
Zilebesiran Development Funding Liability — Payments Made($M) | -5.30 | -5.30 | -5.30 | ||||||||||
1.00% Convertible Senior Notes due 2027 — Estimated Fair Value (Level 2)($M)3 | 392 | 434 | 458 | 534 | 653 | 1,110 | 1,020 | ||||||
1.00% Convertible Senior Notes due 2027 — Carrying Value($M) | 362 | 361 | 361 | 361 | 394 | 1,020 | |||||||
0.00% Convertible Senior Notes due 2028 — Carrying Value($M) | 651 | 650 | 649 | 647 | 646 | ||||||||
0.00% Convertible Senior Notes due 2028 — Estimated Fair Value (Level 2)($M) | 606 | 607 | 615 | 637 | 655 | ||||||||
Stock-Based Compensation (SBC) Expense — Total Recognized($M)4 | 79.1 | 86.6 | 70.2 | 71.6 | 108 | 112 | 56.7 | 91.6 | 45.8 | 89.3 | 45.4 | 42 | |
SBC Expense Allocated to Research & Development($M) | 32.9 | 35.9 | 30.1 | 31.3 | 48.7 | 49.5 | 23.8 | 40.6 | 19.8 | 48.1 | 19.2 | 19.1 | |
SBC Expense Allocated to Selling, General & Administrative($M) | 46.3 | 50.7 | 40 | 40.3 | 59.5 | 62.1 | 32.9 | 51 | 26 | 41.2 | 26.1 | 22.9 | |
SBC Capitalized into Inventory($M) | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 | 0.80 | 0.80 | 0.80 | 0.80 | 0.90 | |
Stock Options Exercised — Total Shares(M) | 0.10 | 0.18 | 0.10 | 0.62 | 0.56 | 0.42 | 0.79 | 1.26 | 0.22 | ||||
Property, Plant & Equipment (PP&E), Net($M)4 | 615 | 554 | 518 | 513 | 502 | 500 | 499 | 503 | 507 | 517 | 524 | 526 | |
Operating Lease Right-of-Use (ROU) Assets($M) | 178 | 183 | 189 | 195 | 191 | 192 | 197 | 191 | 196 | 198 | 196 | 200 | |
Operating Lease Liabilities — Noncurrent($M) | 203 | 211 | 218 | 225 | 223 | 224 | 230 | 230 | 236 | 239 | 238 | 243 | |
Operating Lease Liabilities — Current($M) | 46.1 | 45.9 | 45.7 | 45.5 | 44.8 | 46.1 | 46 | 41.9 | 42.1 | 41.7 | 41.7 | 41.5 | |
ROU Assets Obtained in Exchange for New Operating Lease Liabilities($M) | 0.50 | 0 | 0 | 8.80 | 3.80 | -1.30 | 9.80 | -0.40 | 1.90 | 7 | 0.80 | ||
Novartis AG (NVS) — Leqvio (inclisiran) Worldwide Net Sales ($M)($M)9 | 506 | 480 | 452 | 335 | 308 | 298 | 257 | 223 | 198 | 182 | 151 | 123 | |
Novartis AG (NVS) — Leqvio United States Net Sales ($M)($M) | 234 | 214 | 166 | 164 | 146 | 138 | 127 | 116 | 101 | 94 | 74 | ||
Novartis AG (NVS) — Leqvio Rest of World Net Sales ($M)($M) | 272 | 266 | 286 | 171 | 162 | 160 | 130 | 107 | 97 | 88 | 77 | ||
Novartis AG (NVS) — Leqvio Worldwide Net Sales YoY Growth at Constant Currency (%)(%) | 63.0% | 59.0% | 69.0% | 46.0% | 54.0% | 61.0% | 72.0% | 83.0% | 119.0% | 134.0% | 139.0% | 190.0% | |
Novartis AG (NVS) — Leqvio Worldwide Net Sales YoY Growth in USD (%)(%) | 64.0% | 61.0% | 76.0% | 50.0% | 56.0% | 64.0% | 70.0% | 81.0% | 120.0% | 133.0% | 136.0% | 193.0% | |
Novartis AG (NVS) — Leqvio United States Net Sales YoY Growth (%)(%) | 60.0% | 55.0% | 31.0% | 41.0% | 45.0% | 47.0% | 72.0% | 68.0% | 84.0% | 114.0% | 100.0% | ||
Novartis AG (NVS) — Leqvio Rest of World Net Sales YoY Growth at Constant Currency (%)(%) | 65.0% | 63.0% | 106.0% | 52.0% | 63.0% | 74.0% | 74.0% | 99.0% | 177.0% | 165.0% | 188.0% | ||
Novartis AG (NVS) — Leqvio Rest of World Net Sales YoY Growth in USD (%)(%) | 68.0% | 66.0% | 120.0% | 60.0% | 67.0% | 82.0% | 69.0% | 98.0% | 177.0% | 159.0% | 185.0% | ||
Novartis AG (NVS) — Leqvio U.S. Months-of-Therapy Equivalent Prescriptions (MOTRx) YoY Growth (%)(%) | 60.0% | 49.0% | 41.0% | 56.0% | 44.0% | 56.0% | 70.0% | ||||||
Novartis AG (NVS) — U.S. Advanced Lipid-Lowering Market MOTRx YoY Growth (%)(%) | 46.0% | 37.0% | 34.0% | 35.0% | 35.0% | 35.0% | 37.0% | ||||||
Sanofi (SNY) — Qfitlia (fitusiran) Worldwide Net Sales (€M)(€M)3 | 8 | 7 | 5 | 4 | 4 | 1 | 0 | ||||||
Sanofi (SNY) — Qfitlia United States Net Sales (€M)(€M) | 7 | 7 | 5 | 4 | 4 | 1 | 0 | ||||||
Sanofi (SNY) — Qfitlia Europe Net Sales (€M)(€M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Sanofi (SNY) — Qfitlia Rest of World Net Sales (€M)(€M) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Regeneron Pharmaceuticals (REGN) — Direct Clinical R&D Spend on Pozelimab & Cemdisiran (C5 siRNA, $M)($M) | 21.4 | 23.7 | 17.5 | 21.6 | 16.5 | 16.3 | 12.8 | 30.1 | 17.6 | 19.8 | 12 | 17.6 | |
U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products (FRED: DNRGRC1Q027SBEA, SAAR $B)($M) | 3,859 | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | |
Total Revenues (GAAP)($M)14 | 1,458 | 1,291 | 1,167 | 1,097 | 1,249 | 774 | 594 | 593 | 501 | 660 | 494 | 440 | |
Cost of Goods Sold & Collaborations (GAAP)($M) | 362 | 298 | 208 | 268 | 197 | 142 | 70.2 | 103 | 82 | 67.3 | 54.6 | 72 | |
Research & Development Expenses (GAAP)($M) | 409 | 413 | 365 | 372 | 359 | 324 | 265 | 300 | 271 | 294 | 261 | 272 | |
Selling, General & Administrative Expenses (GAAP)($M) | 342 | 348 | 323 | 325 | 322 | 323 | 240 | 295 | 221 | 248 | 211 | 198 | |
Total Operating Costs and Expenses (GAAP)($M) | 1,112 | 1,060 | 899 | 965 | 881 | 790 | 576 | 698 | 578 | 611 | 538 | 556 | |
Operating Income (Loss) (GAAP)($M) | 346 | 231 | 269 | 132 | 368 | -16.2 | 18.1 | -105 | -76.9 | 48.6 | -43.4 | -116 | |
Interest Income($M) | 30.9 | 28.1 | 26.6 | 26.6 | 28.7 | 27.5 | 28.7 | 31 | 32.1 | 29.2 | 29.6 | 30.4 | |
Interest Expense (Including Non-Cash Royalty Liability Interest)($M) | 84.4 | 82.1 | 69.3 | 65.4 | 67.5 | 61.5 | 58.3 | 39 | 34.4 | 33.3 | 35.3 | 31.3 | |
Income (Loss) Before Income Taxes($M) | 296 | 178 | 222 | 86.3 | 281 | -41.3 | -2.40 | -194 | -109 | -11.2 | -63.6 | -138 | |
Provision for (Benefit from) Income Taxes($M) | -1,872 | 13.3 | 15.7 | -25.3 | -12.1 | 30.9 | 15.9 | -110 | 2.90 | 5.70 | 2.30 | 0.20 | |
Net Income (Loss) (GAAP)($M) | 2,167 | 165 | 206 | 112 | 293 | -72.2 | -18.3 | -83.8 | -112 | -16.9 | -65.9 | -138 | |
Diluted Earnings (Loss) Per Share (GAAP)($) | 15.72 | 1.21 | 1.51 | 2.14 | -0.55 | -0.14 | -0.87 | -0.13 | -0.52 | ||||
Basic Earnings (Loss) Per Share (GAAP)($) | 16.19 | 1.23 | 1.55 | 2.23 | -0.55 | -0.14 | -0.87 | -0.13 | -0.52 | ||||
Weighted-Average Diluted Shares Outstanding(M) | 138 | 138 | 138 | 137 | 131 | 130 | 129 | 127 | 126 | ||||
Weighted-Average Basic Shares Outstanding(M) | 134 | 134 | 133 | 131 | 131 | 130 | 129 | 127 | 126 | ||||
Cash, Cash Equivalents and Marketable Securities22 | |||||||||||||
Cash and Cash Equivalents($M) | 1,754 | 1,708 | 1,711 | 1,657 | 1,490 | 1,114 | 1,020 | 969 | 1,100 | 969 | 682 | 813 | |
Marketable Debt & Equity Securities($M) | 1,833 | 1,600 | 1,298 | 1,251 | 1,234 | 1,744 | 1,605 | 1,720 | 1,672 | 1,646 | 1,678 | 1,616 | |
Accounts Receivable, Net($M) | 1,085 | 913 | 884 | 778 | 965 | 567 | 418 | 405 | 354 | 310 | 321 | 328 | |
Inventories (Current)($M) | 106 | 97.1 | 84 | 82.7 | 75.4 | 71.7 | 65.6 | 78.5 | 76 | 84 | 94 | 89.1 | |
Prepaid Expenses and Other Current Assets($M) | 335 | 302 | 242 | 282 | 188 | 147 | 152 | 117 | 145 | 155 | 202 | 126 | |
Total Current Assets($M) | 5,113 | 4,620 | 4,219 | 4,051 | 3,953 | 3,644 | 3,268 | 3,295 | 3,355 | 3,173 | 2,989 | 2,983 | |
Property, Plant and Equipment, Net($M) | 615 | 554 | 518 | 513 | 502 | 500 | 499 | 503 | 507 | 517 | 524 | 526 | |
Operating Lease Right-of-Use Assets($M) | 178 | 183 | 189 | 195 | 191 | 192 | 197 | 191 | 196 | 198 | 196 | 200 | |
Deferred Tax Assets($M) | 2,007 | 114 | 117 | 126 | 98.6 | 104 | 107 | 117 | 10.1 | ||||
Other Noncurrent Assets (Including Long-Term Inventory)($M) | 60.3 | 65.1 | 63.6 | 59.5 | 55.8 | 57.2 | 73.8 | 65.3 | 77.6 | 71.9 | 67.5 | 61.9 | |
Total Assets($M) | 7,995 | 5,559 | 5,130 | 4,966 | 4,852 | 4,566 | 4,214 | 4,240 | 4,205 | 4,010 | 3,824 | 3,830 | |
Accounts Payable($M) | 135 | 108 | 127 | 116 | 118 | 102 | 97.4 | 88.4 | 70.8 | 74 | 78.1 | 55.5 | |
Accrued Expenses($M) | 1,236 | 1,096 | 947 | 1,080 | 1,154 | 919 | 704 | 794 | 946 | 809 | 699 | 713 | |
Deferred Revenue (Contract Liabilities, Current)($M) | 11.7 | 4 | 3.20 | 4.80 | 2.50 | 15.1 | 28.2 | 55.5 | 71 | 69 | 76.8 | 103 | |
Operating Lease Liabilities (Current)($M) | 46.1 | 45.9 | 45.7 | 45.5 | 44.8 | 46.1 | 46 | 41.9 | 42.1 | 41.7 | 41.7 | 41.5 | |
Total Current Liabilities($M) | 2,063 | 1,513 | 1,350 | 1,466 | 1,556 | 1,301 | 1,076 | 1,186 | 1,221 | 1,055 | 942 | 968 | |
Operating Lease Liabilities, Net of Current Portion($M) | 203 | 211 | 218 | 225 | 223 | 224 | 230 | 230 | 236 | 239 | 238 | 243 | |
Other Noncurrent Liabilities($M) | 10.6 | 9.20 | 7.60 | 7.60 | 9.80 | 10.9 | 5.90 | 5 | 358 | 350 | 320 | 308 | |
Total Liabilities($M) | 4,391 | 4,205 | 4,054 | 4,177 | 4,618 | 4,315 | 4,098 | 4,173 | 4,173 | 4,013 | 4,044 | 4,051 | |
Accumulated Deficit($M) | -4,165 | -6,332 | -6,497 | -6,703 | -7,160 | -7,412 | -7,345 | -7,288 | -7,204 | -7,092 | -7,076 | -7,010 | |
Total Stockholders' Equity (Deficit)($M) | 3,604 | 1,354 | 1,075 | 789 | 580 | 555 | 426 | 67.1 | 32.4 | -3.10 | -219 | -221 | |
Common Shares Outstanding at Period End(M) | 134 | 134 | 133 | 132 | 132 | 131 | 130 | 129 | 129 | 128 | 126 | 126 | |
Net Cash Provided by (Used in) Operating Activities($M)7 | 341 | 327 | 70.5 | 218 | 297 | 130 | -120 | -94.7 | 43.7 | 124 | -81.5 | -29.8 | |
Capital Expenditures (Purchases of Property, Plant & Equipment)($M) | -69.8 | -34.7 | -21.8 | -23.3 | -12.1 | -14.3 | -9 | -9.10 | -4.20 | -8 | -13 | -15.3 | |
Depreciation and Amortization($M) | 14.5 | 13.9 | 13.6 | 13.5 | 13.8 | 13.9 | 14.4 | 14.2 | 14 | 15 | 13.5 | 13.5 | |
Stock-Based Compensation Expense($M) | 79.1 | 86.6 | 70.2 | 71.6 | 108 | 112 | 56.7 | 91.6 | 45.8 | 89.3 | 45.3 | 42 | |
Net Cash Used in Investing Activities($M) | -312 | -364 | -25.5 | -37.2 | 501 | -141 | 114 | -52.9 | -30.2 | 33.9 | -67.6 | -241 | |
Net Cash Provided by Financing Activities($M) | 18.4 | 36.2 | 15.7 | -8.90 | -420 | 77.7 | 46.1 | 31 | 103 | 132 | 28.9 | 39.2 | |
Cash Paid for Interest($M) | 73.3 | 58.1 | 64.2 | 59.1 | 52.1 | 38.5 | 68.9 | 12.3 | 16.1 | 8.20 | 30.9 | 5.40 | |
Cash Paid for Income Taxes, Net of Refunds($M) | 15.1 | 12.4 | 2.40 | 12.7 | 1.30 | -1.90 | 3 | 6.20 | 4.60 | 1.60 | 2 | ||
3 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY, CIK 0001178670) operates on a calendar fiscal year ending December 31 (latest completed fiscal year: FY2025 ended December 31, 2025; latest completed fiscal quarter: Q3 2026 / FY2026Q3 ended September 30, 2026). Alnylam manages and reports its business as a single global biopharmaceutical operating segment focused on RNA interference (RNAi) therapeutics.
- Commercial operations center on two wholly-owned RNAi franchises and two partnered commercial RNAi medicines: (1) the TTR Amyloidosis Franchise ($1,226.4M in Q3 2026 / $2,487.5M in FY2025; +145% YoY at CER in Q3 2026), comprising subcutaneous AMVUTTRA (vutrisiran, $1,182.9M in Q3 2026 / $2,213.4M in FY2025 following March 2025 FDA approval in ATTR-CM) and intravenous ONPATTRO (patisiran, $43.5M in Q3 2026 / $274.1M in FY2025); (2) the Ultra-Rare Disease Franchise ($136.4M in Q3 2026 / $499.6M in FY2025; +12% YoY at CER in Q3 2026), comprising GIVLAARI (givosiran for AHP, $78.0M in Q3 2026 / $289.2M in FY2025) and OXLUMO (lumasiran for PH1, $58.5M in Q3 2026 / $210.4M in FY2025); and (3) Partnered Royalty & Collaboration Programs, led by Leqvio (inclisiran, $860M global net sales by Novartis in Q3 2026 / $3,063M in FY2025), Qfitlia (fitusiran, €31M global net sales by Sanofi in Q3 2026), Roche ($2.8B Zilebesiran alliance; $265.2M RPO at Q3 2026), and Regeneron ($232.9M RPO at Q3 2026).
- Every brand is disaggregated across United States, Europe, and Rest of World (ex-U.S. & Europe) net product revenues alongside reported YoY % and Constant Exchange Rate (CER) YoY % growth rates, intra-year full-year guidance revisions, Gross-to-Net (GTN) rebate and chargeback reserve rollforwards ($419.5M ending reserve at Q3 2026), inventory by manufacturing stage ($113.0M total current + noncurrent inventory at Q3 2026), Blackstone royalty monetization and Level 3 development funding liabilities, functional R&D and SG&A expenses, Non-GAAP reconciliations, global workforce & ESG metrics, and standalone UK statutory accounts for wholly-owned subsidiary Alnylam UK Limited (#08871372, £84.60M turnover and 121 average employees in FY2025).
- Under U.S. GAAP, Alnylam does not file parent-only standalone financial statements (Form 10-K omits Schedule I), so no Consolidated − Parent-only subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'over X patients' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (8)
- Commercial Patients on Therapy Worldwide (ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO) — Excluded because management disclosed patient counts exclusively as lower-bound approximations ('over X commercial patients worldwide', e.g., 'over 5,060' for AMVUTTRA/ONPATTRO and 'over 720' for GIVLAARI at Q3 2024) in quarterly earnings releases and discontinued quarterly patient-count reporting in FY2025–FY2026 following the ATTR-CM launch; exact point values in the SASB HC-BP-000.A table were only published for 3 years (FY2021–FY2023) and omitted from the 2024 and 2025 Corporate Responsibility Reports.
- Compassionate Use / Early Access Program (EAP) Patient Counts — Excluded because annual Corporate Responsibility Reports disclose EAP patients only as lower-bound approximations ('960+ patients across 54 countries').
- U.S. TTR Channel Inventory Days on Hand — Excluded because management only disclosed exact days-on-hand in two quarterly earnings calls (Q2 2026: ~11 days; Q3 2026: ~15 days), falling short of the 3-consecutive-quarter requirement.
- U.S. Health System & Cardiology Payer Coverage Rates for AMVUTTRA in ATTR-CM — Excluded because management disclosed coverage milestones predominantly as qualitative or bound figures ('>90% of commercial lives', 'over 170 health systems') across 2025–2026 launch updates.
- Clinical Pipeline Patient Enrollment Counts (SASB HC-BP-000.B / Clinical Trial Disclosures) — Excluded because exact trial enrollment totals across Phase 1/2/3 studies were only tabulated in the 2021–2023 Corporate Responsibility Reports and not reported for FY2024 or FY2025.
- Initial Full-Year Financial Guidance Issued in January/February — Excluded as a standalone row because initial guidance is issued only once per year and initial sub-franchise guidance for TTR and Rare had only a single completed year; the complete quarterly guidance progression and year-end guidance history are presented in the Consolidated Commercial Execution & Full-Year Financial Guidance Progression group.
- Legacy Partner Collaboration Sub-Series with Discontinued Activity (Sanofi Collaboration Revenue ended in FY2020; Novartis Reimbursed R&D ended in FY2020; Sanofi Reimbursed R&D ended in Q1 2021; Vir Biotechnology Reimbursed R&D ended in Q1 2022; Vir Biotechnology RPO ended in Q4 2022; Vir Biotechnology Deferred Revenue ended in Q4 2018) — Excluded due to lack of data in the 3 most recent quarters or 2 most recent fiscal years.
- Strategic Collaborations, Partnered Royalty Streams & RPO Backlog (Key #4) › Net Revenues from Collaborations (Total) › Vir Biotechnology Collaboration Revenue (Annual) — Excluded due to insufficient recent consecutive periods.
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
TTR Amyloidosis Franchise — AMVUTTRA & ONPATTRO Commercial Performance (Key #1)
- Total TTR Franchise YoY Revenue Growth at Constant Exchange Rate (CER) (%)17 kỳ
- AMVUTTRA (vutrisiran) YoY Revenue Growth at Constant Exchange Rate (CER) (%)13 kỳ
- ONPATTRO (patisiran) YoY Revenue Growth at Constant Exchange Rate (CER) (%)14 kỳ
- Total TTR Franchise Net Product Revenues (AMVUTTRA + ONPATTRO) ($M)11 kỳ
Ultra-Rare Disease Franchise — GIVLAARI & OXLUMO Commercial Performance (Key #2)
- Total Rare Franchise YoY Revenue Growth at Constant Exchange Rate (CER) (%)11 kỳ
- GIVLAARI (givosiran) YoY Revenue Growth at Constant Exchange Rate (CER) (%)16 kỳ
- OXLUMO (lumasiran) YoY Revenue Growth at Constant Exchange Rate (CER) (%)16 kỳ
- Total Rare Franchise Net Product Revenues (GIVLAARI + OXLUMO) ($M)11 kỳ
Consolidated Commercial Execution & Full-Year Financial Guidance Progression (Key #3)
Strategic Collaborations, Partnered Royalty Streams & RPO Backlog (Key #4)
- Royalty Revenue YoY Growth (As Reported) (%)17 kỳ
- Net Revenues from Collaborations YoY Growth (As Reported) (%)15 kỳ
- Remaining Performance Obligations (RPO) — Regeneron Collaboration Transaction Price ($M)25 kỳ
- Net Revenues from Collaborations (Total) ($M)38 kỳ
- Royalty Revenue (Novartis Leqvio & Sanofi Qfitlia) ($M)23 kỳ
- Contract Liabilities (Deferred Collaboration Revenue) — Current Balance ($M)35 kỳ
Gross-to-Net (GTN) Rebate & Chargeback Reserves, Working Capital & Supply Chain (Key #5)
- Blackstone Sale of Future Royalties (Leqvio) — Effective Interest Rate (%)18 kỳ
- Distributor Concentration — Major Customer 'Distributor A' Share of Total Revenues (%)8 kỳ
- Gross-to-Net (GTN) Accrued Rebates, Chargebacks & Discounts — Ending Reserve Balance ($M)14 kỳ
- Inventories by Manufacturing Stage — Total Inventories (Current + Noncurrent) ($M)26 kỳ
- Accounts Receivable Disaggregation — Total Accounts Receivable, Net ($M)34 kỳ
- Accrued Expenses — Total Current Balance ($M)43 kỳ
R&D Cost Structure, Non-GAAP Reconciliation, Royalty Monetization & Capital Structure
- GAAP Research & Development Expenses (Total) ($M)43 kỳ
- GAAP Selling, General & Administrative Expenses (Total) ($M)37 kỳ
- Non-GAAP Operating Income (Loss) ($M)40 kỳ
- Blackstone Leqvio Sale of Future Royalties — Noncurrent Liability Carrying Value ($M)27 kỳ
- 1.00% Convertible Senior Notes due 2027 — Estimated Fair Value (Level 2) ($M)11 kỳ
- Stock-Based Compensation (SBC) Expense — Total Recognized ($M)43 kỳ
- Property, Plant & Equipment (PP&E), Net ($M)43 kỳ
Workforce, Real Estate Footprint, Executive Pay & Corporate Responsibility (ESG)
- Global Full-Time Equivalent (FTE) Employees (Form 10-K Item 1)9 kỳ
- Women in Global Workforce (%) (%)5 kỳ
- Board of Directors — Total Members5 kỳ
- Workplace Safety — Total Recordable Incident Rate (TRIR per 100 FTEs) (×)7 kỳ
- Corporate Headquarters — 675 West Kendall Street, Cambridge, MA (Leased Area, sq ft)9 kỳ
- Annual Incentive Program (AIP) Corporate Performance Modifier (% of Target Payout) (%)8 kỳ
- Scope 1 Direct Greenhouse Gas (GHG) Emissions (Metric Tons CO2e)6 kỳ
Alnylam UK Limited (#08871372 — Wholly-Owned UK Commercial & R&D Subsidiary Statutory Filings)
Partnered RNAi Commercialization (Novartis Leqvio, Sanofi Qfitlia & Regeneron) & Industry Macro (External)
- Novartis AG (NVS) — Leqvio (inclisiran) Worldwide Net Sales ($M) ($M)22 kỳ
- Sanofi (SNY) — Qfitlia (fitusiran) Worldwide Net Sales (€M) (€M)7 kỳ
- Regeneron Pharmaceuticals (REGN) — Direct Clinical R&D Spend on Pozelimab & Cemdisiran (C5 siRNA, $M) ($M)17 kỳ
- U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products (FRED: DNRGRC1Q027SBEA, SAAR $B) ($M)35 kỳ
Financial Statements Context (GAAP Income Statement, Balance Sheet & Cash Flows)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Alnylam Pharmaceuticals
- Alnylam Form 8-K (FY2026Q3 Earnings Release, filed 2026-10-29) ↗
- Alnylam Form 8-K (FY2025Q4 Earnings Release, filed 2026-02-12) ↗
- Alnylam UK Limited (#08871372) — Annual Report FY2025 (with FY2024 comparative) ↗
- Alnylam 2025 Corporate Responsibility Report ↗
- Alnylam Form 8-K (FY2025Q3 Earnings Release, filed 2025-10-30) ↗
- Alnylam Form 10-K (FY2025 Form 10-K, filed 2026-02-12) ↗
- Alnylam Form 10-Q (filed 2026-10-29) ↗
- Alnylam Form 10-K (filed 2026-02-12) ↗
- Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗
- Novartis Form 6-K (0001114448-26-000014) ↗
- Novartis Form 6-K (0001114448-26-000007) ↗
- Sanofi Q3 2026 Net Sales Workbook (2026_10_30_Sanofi_Q3_2026_SALES_EN.xlsx) ↗
See a number that looks wrong?